Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Cisplatin Induction in Stage IIIA N2 NSCLC
NCT00005868Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2000
- Primary completion
- Aug 2002
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective Response Rate. Started Mar 2000; status: completed.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00005868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005868.